Oviduct-specific expression of heterologous recombinant proteins in transgenic birds is a promising technology for the large-scale production of therapeutic proteins in eggs. We describe the production of recombinant human interleukin 1 receptor antagonist (rhIL1RN) in the eggs of transgenic quails. To drive tissue-specific expression of rhIL1RN, a 1.35-kb fragment of the chicken ovalbumin promoter, which contains both the steroid-dependent regulatory element and the negative regulatory element, was used. A transgenic quail was generated by microinjection of a concentrated stock of lentivirus into stage X blastodermal cells.
INTRODUCTION
Transgenic animals are regarded as potential alternative sources of therapeutic recombinant proteins for human medicine [1] . Transgenic insects [2] , mammals [3] , and birds [4] [5] [6] have been used for the production of therapeutic proteins. Of these, transgenic birds have several advantages over other animal species in terms of ease of setup and scaleup, lower costs, and acceptable production yields [7] . In particular, transgenic quail is one of the best systems for producing therapeutic proteins in avian species [1, [8] [9] [10] . A quail can produce as many eggs as a chicken (.300/yr), and has a shorter generation time (i.e., 18 days to hatch and about 2 mo to reach adult body weight [100-130 g] and maturity) [11] . Quails also require less space for husbandry, and less nutritional energy to produce the same amount of egg protein, as they have lower metabolic energy than chickens [12] . In addition, quail is genetically very similar to chicken [13] , which allows the use of identified chicken regulatory elements for tissue-specific expression in quail organs. In the use of birds as bioreactors for producing therapeutic proteins, oviductspecific expression of exogenous genes/proteins is important, since most therapeutic proteins are harmful to the host animal when expressed via a ubiquitous promoter. To solve this problem, the chicken ovalbumin promoter has been used to induce oviduct-specific expression of a therapeutic protein in chickens [5, 6] . The chicken ovalbumin promoter is one of the strongest tissue-specific promoters, giving yields of ovalbumin that exceed 50% of the total egg white protein content [14] . Therefore, the use of the chicken ovalbumin promoter is a promising strategy for constructing avian bioreactors.
In the past decade, many transgenic quails have been produced using viral vectors. Germline transmission of a transgene in quail was first reported using the VSV-G pseudotyped retroviral vector [15] . Neuron-specific expression of GFP was reported using a lentiviral vector and the human synapsin I gene promoter [16] . In addition, the production of single-chain antibody (scFv-Fc) in the egg white of genetically manipulated quails has been reported [17] . Recently, we reported on the ubiquitous expression of GFP in transgenic quails following the transduction of postmigratory gonadal primordial germ cells by a lentiviral vector [8] . However, there has been no report to date on oviduct-specific expression of therapeutic proteins in quails.
In the present study, we describe oviduct-specific expression using the chicken ovalbumin promoter and a lentiviral vector system in transgenic quail. Recombinant human interleukin (IL) 1 receptor antagonist (rhIL1RN) was expressed in the oviductal tubular gland cells of transgenic quails. The rhIL1RN has been shown to be efficacious in the treatment of inflammatory disorders, such as sepsis syndrome and rheumatoid arthritis [18] . Oviduct-specific expression of the transgene was directed by a 1.35-kb region of the regulatory sequences upstream of the chicken ovalbumin gene. Germline transmission of the transgene was confirmed, and the functionality of the rhIL1RA produced in the transgenic quail was analyzed.
MATERIALS AND METHODS

Experimental Animals and Animal Care
The care and experimental use of Japanese quails (Coturnix japonica) were approved by the Institute of Laboratory Animal Resources, Seoul National University (SNU-070823-5). Japanese quails were maintained in a standard management program at the University Animal Farm, Seoul National University, Korea. The procedures used for animal management, reproduction, and embryo manipulation followed the standard operating protocols of our laboratory.
Vector Construction and Lentiviral Vector Production
The 1.35-kb fragment of the regulatory region upstream of the chicken ovalbumin gene was amplified by PCR and cloned into the pLXSN vector (Clontech, Mountain View, CA), generating pLXSN-OVA1.35. The coding sequence for rhIL1RN was obtained from a human blood cDNA template using RT-PCR. For efficient secretion of protein in the oviductal tubular gland cells, the original signal peptide of hIL1RN was replaced with the signal peptide for chicken lysozyme. The eventual vector, pLTOKiGW, was constructed by inserting the EcoRV/NotI fragment of OVA1.35-rhIL1RN into the PmeI site of pLTiGW. The structure of the pLTOKiGW lentiviral construct is shown in Figure 1A . For the production of lentiviruses, 293FT cells were transfected with pLTOKiGW and the ViraPower packaging mixture (Invitrogen, Carlsbad, CA) using the calcium phosphate coprecipitation method. After 48 h of incubation, viral particles were harvested and concentrated by ultracentrifugation. To determine its titer, nonconcentrated viral supernatant was serially diluted and subsequently transfected to 3 3 10 5 quail embryonic fibroblasts in a 6-well cell culture plate, which resulted in 1-10 3 10 6 TU/ml of titer by endpoint dilution titration (data not shown).
Production and Analysis of Transgenic Quails
Freshly laid eggs from wild-type plumage (WP:
Japanese quail were swabbed with 70% ethanol and positioned with the longer side facing upwards for at least 4 h at room temperature, as described previously [9] . A window (5-mm diameter) was then made in the each egg using fine tweezers, and 2-3 ll of concentrated lentivirus was injected into the subgerminal cavity of the blastoderm at stage X. The window was then double sealed with paraffin film, and the egg was incubated with the pointed end facing downwards until hatching. To confirm stable integration of the transgene, genomic DNA samples were extracted from the blood of hatched quails using the PUREGENE DNA purification kit (Gentra Systems, Minneapolis, MN), and PCR was performed on these DNA samples using the KG858 primer set (Supplemental Table S1 ; all Supplemental Data are available online at www.biolreprod.org). For Southern blot analysis, 10 lg of genomic DNA was digested with restriction enzyme (EcoRI or EcoRV), fractionated on a 1.2% agarose gel, and then transferred to a Hybond N þ nylon membrane (GE Healthcare, Piscataway, NJ). A specific probe was generated from a 410-bp PCR product that was amplified from pLTOKiGW using GFP primer set (Supplemental Table S1 ). The membrane was hybridized with the probe labeled with [a- 32 P]dCTP using a random primer labeling kit (Takara, Madison, WI), according to the manufacturer's instructions. After hybridization, the membranes were washed, exposed on an intensifying plate, and analyzed with the BAS 2500 phosphoimager (Fujifilm, Tokyo, Japan).
Identification of Transgene-Flanking Regions and Zygosity Analysis
The DNA sequence flanking the transgene integration site was identified using DNA Walking SpeedUp Premix Kit-II (Seegene, Seoul, Korea), according to the manufacturer's protocol. The products of the final round of DNA Walking PCR were excised from the agarose gel, purified with the Power Gel Extraction Kit (Takara), and directly cloned into pGEM-T Easy vector (Promega, Madison, WI), as described previously [8] . The cloned plasmids were sequenced with the ABI Prism 3730 XL DNA Analyzer (Applied Biosystems, Foster City, CA), and the transgene-flanking region was identified by comparing the sequence of the cloned plasmid insert with chicken genome sequences using the BLAST Assembled Genomes (http://blast.ncbi.nlm.nih.gov). For the zygosity analysis, a WT primer set, which amplifies a 493-bp product from the wild-type allele, was designed based on the flanking sequence (Supplemental Table S1 ).
Transgene Expression Analysis
Total RNA and protein samples were prepared from fresh tissue samples (;50 mg) using the TRIZOL reagent (Invitrogen). For Northern blotting, total RNA was electrophoresed on a 1.2% formaldehyde gel and transferred to a Hybond N þ nylon membrane (GE Healthcare). To generate the rhIL1RN probe and GFP probe, 442-bp and 410-bp PCR products were amplified from pLTOKiGW using the rhIL1RN and GFP primer sets, respectively. For the GAPDH probe, a 264-bp PCR product was amplified from cDNA of a quail (Supplemental Table S1 ). The blot was hybridized with a DIG-labeled RNA probe that was prepared using DIG RNA Labeling kit (Roche Applied Science, Indianapolis, IN). Hybridization signals were detected by a chemiluminescence reaction with CDP-Star (Roche Applied Science). For the detection of rhIL1RN protein, 10 lg of total protein from each tissue, 2 ll of egg white, or 5 ll of blood plasma were electrophoresed on 15% polyacrylamide gel, transferred to a polyvinylidene fluoride membrane (Millipore, Billerica, MA), and rhIL1RN protein was detected by blotting with rabbit anti-human IL1RN antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology) secondary antibody. Recombinant hIL1RN produced in Escherichia coli (R&D Systems, Minneapolis, MN) was used as a control. For quantification of rhIL1RN in the egg whites from transgenic quails, a matrix effect of the egg white was tested using 100%, 50%, 25%, 12.5%, 6.3%, 3.1%, 1.6%, and 0.8% of the IL1RN control samples diluted with egg white. The egg white samples were diluted 200-fold in PBS-T (0.1% Tween 20 in 13 PBS), and the rhIL1RN concentrations were determined using the Human IL-1ra/IL-1F3 Quantikine ELISA Kit (R&D Systems). In addition, purified IL1RN samples were prepared for mass spectrometry using SDS-PAGE, and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Purification of rhIL1RN from Egg White
The egg white was manually separated from the yolk, followed by 4-fold dilution in deionized, sterilized water, and an equal volume of 2 M ammonium sulfate was added. After 30 min of stirring, the precipitate was centrifuged for 30 min at 3200 3 g. The supernatant was collected and filtered through a 0.22-lm bottle top filter. To remove ovalbumin and ovotransferrin, affinity column chromatography was performed using Blue HP (GE Healthcare). The elution fraction of Blue HP was purified by size exclusion column chromatography using Superdex 200 (GE Healthcare) and monitored by absorbance at 280 nm (AKTA purifier; GE Healthcare).
Immunohistochemistry
The G 3 transgenic quails were killed and the magnum portion of the oviduct was collected. The tissues were embedded in paraffin, sectioned at 4-lm thickness, and placed on APES-treated (silanized) slides. The slides were blocked for 1 h in PBS that contained 10% normal goat serum, incubated for 1 h with the rabbit anti-human IL1RN primary antibody (1:100 dilution; Santa Cruz Biotechnology), and then with the biotinylated goat anti-IgG secondary antibody (1:200; Vector Laboratories, Burlingame, CA). After incubation with streptavidin-conjugated alkaline phosphatase for 30 min, the slides were reacted at room temperature for 25 min with the Vector Red reagent (Vector Laboratories), according to the manufacturer's protocol.
Glycosidase Treatment of rhIL1RN Derived from Transgenic Quail
For the enzymatic release of N-linked carbohydrates, 1 ll of egg white from the transgenic quail and nontransgenic quail were deglycosylated using the NGlycosidase F Deglycosylation Kit (Roche Applied Science), according to the manufacturer's instructions. The mixtures were boiled for 5 min and subjected to SDS-PAGE and Western blotting, as described above.
Bioassay for rhIL1RN in Quail Egg White PRODUCTION OF rhIL1RN IN TRANSGENIC QUAIL after incubation (20% hatch rate), 59 (81.9%), including 34 males and 25 females, were sexually mature after 2 mo. The 59 G 0 founders were mated with nontransgenic wild-type quails. The integration of transgene was screened by PCR analysis of extracted genomic DNA in a total 670 G 1 progenies from G 0 founders. Subsequently, one of the 59 (1.7%) G 0 founders, OK17, produced 68 G 1 quails; one of these progeny (OKG1-1, female, 1.5%) was confirmed as a transgenic quail (Fig. 1B) . We then crossed the G 1 transgenic OKG1-1 with a nontransgenic wild-type male quail, which resulted in the production of five (27.8%) G 2 transgenic offspring; three females and two males (OK G2-7, OK G2-9, OK G2-13, OK G2-14, and OK G2-17; Supplemental Fig. S1 ). Given the low number of G 2 transgenic quails, we crossed the G 2 transgenic offspring with nontransgenic quails, thereby hatching 82 G 3 transgenic offspring. These hemizygous transgenic offspring were crossed with each other, so that, eventually, 14 homozygous transgenic quails were hatched (Supplemental Table S2 ).
To identify the location of the transgene in the quail genome, we analyzed the genomic DNA of a transgenic quail using the DNA Walking SpeedUp system (Seegene). The transgene was integrated at the seventh intron of the conserved oligomeric Golgi complex protein 5 (COG5) gene, which is located on the distal p arm of chromosome 1 (Fig. 1C, and  Supplemental Figs. S2 and S3) . Southern blot analyses of genomic DNAs revealed that the transgenic quails carried a single copy of the transgene, which was stably integrated in the genome, because, in G 1 and G 4 progeny, the predicted fragment of 1.3 kb was detected following double digestion with EcoRI and EcoRV, and one junction fragment was detected by EcoRV digestion (Fig. 1D) . All the hemizygous and homozygous offspring had the same integration site, as they were derived from a single G 1 quail.
Because of transgene integration at the seventh intron of the COG5, we expected that potential disruption of COG5 expression might cause the non-Mendelian inheritance of the hemizygous transgene due to low viability of transgenic chicks. However, COG5 was normally expressed in homozygous offspring as well as hemizygous offspring, indicating that gene integration did not affect the viability of the chicks (Supplemental Fig. S4 ).
Oviduct-Specific Expression of rhIL1RN
Since we used a 1.35-kb fragment of the chicken ovalbumin promoter for the production and accumulation of rhIL1RN protein in quail eggs, we expected the hIL1RN to be expressed specifically in the oviducts of the transgenic quails. The transcription and translation of hIL1RN in quail organs were analyzed in Northern and Western blots, respectively. Total RNA samples from various tissues were hybridized with two antisense RNA probes, the human IL1RN probe and a GFP probe, which detect the human IL1RN and GFP transcripts, respectively (Fig. 1A) . As a result, the expression of both human IL1RN and GFP was found to be strictly restricted to the oviducts of the transgenic quails ( Fig. 2A) . Western blotting with anti-human IL1RN antibody of protein extracts from various tissues showed exclusive expression of hIL1RN in the oviducts (Fig. 2B) . Furthermore, immunohistochemical analysis localized rhIL1RN to the tubular glands of the magnum portion of the oviduct, but not to the adjacent epithelial cells (Fig. 2C) .
Secretion of rhIL1RN into the Egg White
We used the chicken lysozyme signal peptide sequence to ensure secretion of the recombinant protein into the transgenic quail egg white (Fig. 1A) . We used ELISA to measure the yields of rhIL1RN in the egg whites of G 4 hemizygous and homozygous transgenic quails. As illustrated in Figure 3A , the quantities of rhIL1RN varied among individual transgenic quails of both the hemizygous and homozygous generations. Most of the hemizygous transgenic quails produced 40.1-90.2 ng/ml rhIL1RN in the egg white, whereas two of these birds (HT-1 and HT-11) gave higher yields (;200 ng/ml) of rhIL1RN in the egg white. In the homozygous transgenic quails, the level of rhIL1RN secretion ranged from 88.7 to 233.8 ng/ml, which was not significantly higher than that observed for the hemizygous transgenic quails (P ¼ 0.097). During 10 wk of egg laying, rhIL1RN was continuously secreted and accumulated in the egg whites of all the homozygous transgenic quails, although the quantities expressed by individual transgenic hens varied during this period (Fig. 3B) .
To characterize the rhIL1RN protein present in the egg whites of the transgenic quails, we purified the protein and subjected it to mass spectrometric analysis. For purification, affinity column chromatography was conducted with Blue HP, and the elution fraction of Blue HP was purified by size exclusion column chromatography using Superdex 200 (Supplemental Fig. S5 ). Further analysis by mass spectrometry revealed that the rhIL1RN accumulated in the egg white
FIG. 2. Oviduct-specific expression of rhIL1RN in transgenic quails. A)
Northern blot analysis of a G 2 female transgenic quail. Total RNA samples were extracted from various tissues and hybridized with probes for rhIL1RN (labeled hlL1RN in figure) , GFP, and GAPDH. B) Western blot analysis of a G 2 female transgenic quail. Total protein samples from various tissues were resolved on a 15% polyacrylamide gel, and rhIL1RN (hlL1RN) was detected using the anti-rhIL1RN antibody. C) Localization of rhIL1RN by immunohistochemistry. The rhIL1RN protein is visualized in a section of the magnum portion of the oviduct by staining with anti-human IL1RN antibody, with hematoxylin counterstaining of the nuclei. Bar ¼ 20 lm.
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corresponded to the full-length hIL1RN protein (Fig. 4A) . In the Western blot, the 18-kDa rhIL1RN was detected in the egg whites of both hemizygous and homozygous transgenic quails, whereas it was not detected in blood samples taken from the same birds (Fig. 4B) . These results confirm oviduct-specific expression of rhIL1RN in transgenic quails, and show that the molecular mass of rhIL1RN derived from the egg white of transgenic quails and that of rhIL1RN produced in E. coli are different. The latter finding suggests that the rhIL1RN generated in the egg white of transgenic quail undergoes a posttranslational modification, such as glycosylation. Therefore, we examined the glycosylation pattern of the rhIL1RN derived from transgenic quails by subjecting this protein to Nglycosidase F treatment, since hIL1RN has a putative Nglycosylation site. Following treatment with N-glycosidase F, the band for rhIL1RN was shifted downward to about 17 kDa, which corresponded to the molecular mass of the (nonglycosylated) E. coli-derived rhIL1RN (Fig. 4C) .
In Vitro Biologic Activity of rhIL1RN Produced in Transgenic Quails
The biologic activity of the rhIL1RN purified from the egg whites of transgenic quails was examined using the EL4.NOB-1/CTLL-2 coculture system. The murine lymphoma line, EL4.NOB-1, produces IL2 upon stimulation with IL1A and IL1B. Therefore, the activity of IL1RN was measured indirectly by assessing the proliferation rate of CTLL-2, an IL2-dependent murine T-cell line. The rhIL1RN purified from egg white significantly decreased the proliferation of CTLL-2 cells in a dose-dependent manner (Fig. 5) . Moreover, there was no significant difference in the biologic activities of the eggproduced rhIL1RN and anakinra, which is a commercially available rhIL1RN (P . 0.05). This result demonstrates that transgenic quails produce a biofunctional rhIL1RN protein in their egg white.
DISCUSSION
In the present study, we have demonstrated the generation of genetically manipulated quails and the accumulation, via oviduct-specific expression, of biofunctional rhIL1RN in the egg whites of these transgenic quails. In all, 68 G 1 progeny were produced from the OK17 G 0 founder, and one (OKG1-1) of them was a transgenic quail. The OKG1-1 is hemizygous for transgene; thus, we expected 50% of hatched chicks would be transgenic. However, OKG1-1 laid 54 eggs in total, and 24 G 2 chicks hatched. Among them, five chicks were transgenic confirmed using PCR analysis. Moreover, G 2 matings consistently showed only 20% transgenic progeny, and G 3 mating also produced less than 30% transgenic progeny. These Western blot analysis of rhIL1RN in the egg whites and blood samples of homozygous and hemizygous transgenic quails. E. coli-produced rhIL1RN was loaded as a positive control, and the egg white from a wild-type quail was used as a negative control. Transgenic quail-produced, glycosylated rhIL1RN is shifted upwards as compared with E. coli-produced, nonglycosylated rhIL1RN. C) Glycosylation analysis of rhIL1RN produced by transgenic quails. The N-linked glycan chains are deglycosylated using N-glycosidase F, which indicates that transgenic quail-produced hIL1RN contains the normal N-glycosylation site.
PRODUCTION OF rhIL1RN IN TRANSGENIC QUAIL
results suggest that expression of rhILRN or disruption of endogenous gene by transgene integration affects the viability of transgenic embryos.
Initially, we identified the genomic insertion site of the delivered gene in the transgenic quails, and found that the lentiviral transgene was integrated into the seventh intron of the COG5 gene, which is located on the distal p arm of chromosome 1. The COG complex is one of the key determinants of the Golgi apparatus structure, and is involved in intracellular transport and glycoprotein modification [19] . The disruption of one intron of the COG5 gene was not lethal for the transgenic quails, because normal expression of COG5 was observed even in homozygous transgenic quails. One possibility is that the lentiviral transgene integrated at a position in the middle of the seventh intron, such that it did not disrupt the open reading frame of COG5 or the splicing process. Therefore, rhIL1RN in egg whites may be a potential reason for low viability of transgenic chicks.
To achieve oviduct-specific expression of a recombinant protein in transgenic quail, we used the 1.35-kb region of the chicken ovalbumin promoter, which was expected to regulate specific and high-level expression of ovalbumin in the tubular gland cells of the oviduct. The 1.35-kb ovalbumin promoter region contains two major regulatory elements: the steroiddependent regulatory element (SDRE) and the negative regulatory element (NRE). The SDRE, which spans nucleotides À892 to À793, facilitates ovalbumin gene transcription in response to four steroid hormones (i.e., estrogen, progesterone, glucocorticoid, and androgen) [20] . The NRE is a bifunctional element that cooperates with the SDRE to induce ovalbumin gene expression in the presence of steroids, although it represses this expression in the absence of steroids in the oviductal tissues [21, 22] . In addition, the NRE represses ovalbumin gene expression in nonoviductal tissues [23] . In the Northern and Western blot analyses, the transgenic expression of both rhIL1RN and GFP was restricted to oviductal tissues. Immunohistochemical analyses of the oviducts of the transgenic quails showed that recombinant protein synthesis was strictly restricted to the tubular gland cells, in which ovalbumin is synthesized and secreted into the lumen of magnum, while rhIL1RN synthesis was absent from the adjacent epithelial cells. Considering the expression patterns observed in the present study, it appears that the 1.35-kb chicken ovalbumin promoter region that contains the SDRE and NRE elements is effective in inducing oviduct-specific expression of delivered genes in transgenic quails. In a previous report [6] , ectopic expression of a transgene was detected in the ileum, cecum, and colon of a chimeric chicken generated using a vector that included 15 kb of the 5 0 -flanking region and 3 0 -flanking region of the ovalbumin gene, although these regions contain all the regulatory elements implicated in the oviduct specificity and steroid induction of ovalbumin gene expression [24, 25] . In contrast, in the present study, only 1.35 kb of the 5 0 -flanking region was needed to direct oviduct-restricted expression of the rhIL1RN transgene. This means that the large region of regulatory sequences may be dispensable for tissue-specific expression of transgenes in quail. A recent report [5] showed that a vector that contains the SDRE and NRE is sufficient to induce oviduct-specific expression of a transgene. However, in the present study, the quantity of recombinant protein in the egg white was not as high as the yield reported previously. These results indicate that, although the 1.35-kb ovalbumin promoter region used in the present study is definitely sufficient for oviduct-specific expression, it is not sufficient for high-level production of foreign proteins in the quail oviduct. One hypothesis concerns the absence of the 5 0 -untranslated region (UTR) upstream of the protein coding region. Zhu et al. [6] reported a high level (in the milligramper-egg range) of recombinant protein expression in transgenic chickens when they used expression vectors that contained the 5 0 -UTR and 3 0 -UTR sequences of the ovalbumin gene. In addition, Lillico et al. [7] showed that an expression vector that included only the 5 0 -UTR sequences of the chicken ovalbumin gene produced similar amounts of the recombinant protein (in the milligram-per-egg range) in transgenic chickens. One possible explanation is that the 5 0 -UTR of the ovalbumin gene is important for posttranscriptional regulation that increases the efficiency of mRNA translation. Another possible explanation for the low level of rhIL1RN expression seen in the present study is the absence of an estrogen response element (ERE). Once estrogen receptor 1 (ESR1) binds to its ligand, estradiol, it binds to an ERE located in or adjacent to the coding sequence region of the ovalbumin gene. ERE-bound ESR1 interacts with nuclear transcription factors, such as coactivator proteins and components of the TATA binding complex, thereby enhancing ovalbumin gene expression [26, 27] . However, the effect of the ERE is not significant, since ERE did not increase transgene expression in chickens [5] . In general, estrogen produces a cellular environment that stabilizes ovalbumin mRNA in the process of egg white protein synthesis [28, 29] . Estrogen recruits protective proteins that bind to a discrete region within the 3 0 -UTR of its receptor mRNA in the primary target organs, and that protect the mRNA from degradation [30] . Therefore, the inclusion of 3 0 -UTR sequences in expression vectors may be necessary for optimizing the production of recombinant proteins in the eggs of transgenic birds used as bioreactors. Currently, we are trying to develop more efficient promoters that contain positive and negative elements not only to ensure oviduct-specific expression, but also to increase the expression levels of recombinant proteins in transgenic birds.
Silencing or suppression of transgenes is one of the major obstacles to the use of viral vectors for avian transgenesis [15, 31] . However, our current results demonstrate that the integrated transgene is stably transmitted to subsequent generations, and that the transgene expression profiles are conserved from the G 1 to G 4 generation. Similarly, we did not observe any evidence of transgene silencing in a previous study in which EGFP-expressing transgenic quail were generated by the transduction of postmigratory primordial germ cells or stage X embryos [8] .
We found variations in the levels of deposition of rhIL1RN in the egg whites between individual transgenic quails. Since we obtained only one G 1 transgenic quail (OKG1-1) from the G 0 founders, and crossed OKG1-1 to produce subsequent generations, all of the G 3 and G 4 transgenic quails had the same transgene integration site. Therefore, the site of transgene integration does not appear to have a major impact on the level of rhIL1RN expression in transgenic quails. Instead, the genetic backgrounds of the hens or epigenetic factors may affect the transgene expression level. Indeed, the expression level of rhIL1RN in the egg white was higher in most of the homozygous transgenic quails than in the hemizygous transgenic quails (100.3 ng/ml vs. 150.7 ng/ml), although the quantity of rhIL1RN in the homozygous transgenic quails was not twice that in the hemizygous transgenic quails.
The rhIL1RN blocks the biologic activity of naturally occurring IL1, including that produced during the inflammation and cartilage degradation associated with rheumatoid arthritis, by competitively inhibiting the binding of IL1 to the IL1-type receptor [18] . The rhIL1RN is used to reduce the symptoms and slow the progression of structural damage in patients with rheumatoid arthritis [32] . However, rhIL1RN prepared from E. coli differs from native human IL1RN in that it has an additional methionine residue at its aminoterminus, and lacks posttranslational modifications, such as glycosylation. Thus, E. coli-derived rhIL1RN is contraindicated in patients with known hypersensitivity to E. coli-derived proteins [33] . Interestingly, the rhIL1RN purified from the egg whites of transgenic quails in the present study corresponded to the full-length native hIL1RN protein, and had the normal amount of glycosylation. These results suggest that transgenic quail-produced therapeutic proteins may be more effective than E. coli-produced recombinant proteins, without undesirable side effects.
Although the quail is one of the best avian species for producing therapeutic proteins through transgenesis, the scarcity of genetic information on the quail has hindered the development of tissue-specific expression in transgenic quails. Our current data demonstrate that the chicken ovalbumin promoter can drive oviduct-specific transgene expression in transgenic quail, with the objectives of producing biofunctional proteins and a model animal in medicine.
